1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biophytis S.A.

Biophytis S.A.

BPTSY
Biophytis S.A.US flagOther OTC
0.25
USD
- -
- -
105,224.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-34.78
-47.28
-4,302.63
-5,128.3
-4,966.48
-4,182.72
-4,488.51
-1,701.81
-1,053.84
-554.02
-125.41
- -
Free Cash Flow per Basic Share
- -
-53.83
-44.12
-2,724.2
-4,442.94
-3,855.03
-3,639.35
-3,632.55
-664.07
-816.31
-437.63
-96.44
-16.65
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
15.5
3
-3,283.72
-4,325.6
-3,794.08
-3,377.39
-12,705.99
-1,342.2
-737.95
-5.61
-127.44
-48.19
Tangible Book Value per Share
- -
-27.3
-75.29
7,692.43
1,543.52
8,349.59
1,523.92
-2,531.15
-27.01
103.01
-104.46
-48.07
-23.72
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Net Income, GAAP
- -
-1
-1
-5
-8
-11
-14
-19
-26
-31
-24
-17
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
-1
9
3
19
11
-6
1
9
-1
-4
-12
LT Debt
- -
- -
- -
- -
- -
- -
6
4
1
5
4
3
- -
Total Equity
- -
- -
-1
12
5
21
7
-8
2
6
-2
-4
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-105.76
-511.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-95.62%
29.71%
149.47%
Free Cash Flow
62.18%
4.22%
-33.99%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-125.41
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Stanislas Veillet
Full Time Employees
19
Sector
Healthcare
Industry
Biotechnology
Address
Sorbonne University Paris IF France 75005
IPO Date
Feb 10, 2021
CIK
0001768946
Website
biophytis.com
Similar Companies
BetterLife Pharma Inc. (BETRF)
Silence Therapeutics plc (SLN)
Diamyd Medical AB (publ) (DMYD-B.ST)
Microbix Biosystems Inc. (MBX.TO)
Pharma Mar, S.A. (PHM.MC)
Xeno Transplants Corporation (XENO)
Business
Biophytis S.A. Biophytis S.A. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that slow degenerative processes associated with aging and improve functional outcomes for patients with age-related diseases. The company targets key biological resilience pathways to counteract stresses such as inflammatory, oxidative, metabolic, and viral factors leading to conditions like sarcopenia, obesity-related muscle wasting, Duchenne muscular dystrophy (DMD), and retinal diseases; its lead candidate, Ruvembri (BIO101, 20-hydroxyecdysone), is an orally administered small molecule in late-stage development for sarcopenia (Phase 3), obesity (Phase 2 OBA trial launched in 2025), severe COVID-19 respiratory failure (Phase 2/3 COVA), and DMD (pediatric formulation with FDA IND approval via MYODA); its second candidate, Macuneos (BIO201), advances for dry age-related macular degeneration (AMD) and Stargardt disease. Founded in 2006 and headquartered at 14 avenue de l'Opéra in Paris, France, Biophytis operates primarily in Europe and the United States, with subsidiaries in the US and Brazil, and approximately 18-22 employees supporting its drug discovery platform accelerated by AI for longevity research. Recent developments include a €108 million licensing agreement with Blanver for BIO101 commercialization in Latin America; exclusive negotiations and contracts with Chinese and Asian partners, including a joint venture in Hong Kong with up to $20 million investment from a consortium led by RONGHUI RENHE Life Technology to fund the first Phase 3 sarcopenia trial starting early 2026; a co-development agreement with AskHelpU for amyotrophic lateral sclerosis (ALS); €8.6 million refinancing and €2.6 million private placement in 2025 to strengthen its financial position; and strategic expansion into obesity treatment highlighting mobility restoration.

Company News

APIChatGPT

  • newsfilecorp.com

    Biophytis Targets Mobility Restoration in Patients with Obesity

  • newsfilecorp.com

    Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

  • newsfilecorp.com

    Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity

  • newsfilecorp.com

    Biophytis Revolutionizes Sarcopenia

  • newsfilecorp.com

    Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

  • newsfilecorp.com

    Biophytis Unveils Its Outlook Strategies for 2025

  • newsfilecorp.com

    Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference

  • newsfilecorp.com

    Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China